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Simple Summary: Cancer treatments can cause adverse effects such as cancer-related fatigue. Immune checkpoint inhibitors (ICIs) are a relatively new therapy for some cancers and have shown
great promise in helping people. Physical activity has been shown to aid many cancer patients
to overcome adverse effects in traditional chemotherapy, but along with ICIs, it hasn’t been fully
examined. This study was carried out to describe where the current research is now and to find
knowledge gaps to help shape future research with ICIs, physical activity, and cancer outcomes.
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Abstract: Background: Cancer therapies are associated with multiple adverse effects, including
(but not limited to) cancer-related fatigue (CRF). Fatigue is one of the most common side effects of
immune checkpoint inhibitors (ICIs), occurring in up to 25% of patients. Physical activity has been
shown to help reduce CRF through modulating the immune system, and may synergistically aid
in the anti-tumor effects of ICIs. This review describes the nature and scope of evidence for the
effects associated with concurrent physical activity while undergoing ICI therapy. Method: Scoping
review methodology was utilized to identify studies, extract data, and collate and summarize results.
Results: In literature published from January 2010 through to August 2021, only one human study
and three pre-clinical studies met inclusion criteria. Conclusion: Existing evidence supports that
physical activity is associated with decreased treatment-related toxicities such as CRF. However,
further investigation is warranted. The dearth of clinical studies illustrates the need for more research
to address this question, to guide patients and their providers in the application of appropriate
physical activity interventions in those patients undergoing ICI.
Keywords: immune checkpoint inhibitors; physical activity; exercise; exercise therapy; adverse
events; tumor growth; concurrent therapy

published maps and institutional affiliations.

1. Introduction
Copyright: © 2021 by the authors.
Licensee MDPI, Basel, Switzerland.
This article is an open access article
distributed under the terms and
conditions of the Creative Commons
Attribution (CC BY) license (https://
creativecommons.org/licenses/by/
4.0/).

Immune checkpoint inhibitors (ICIs) have demonstrated clinical efficacy in multiple
cancer settings. Since the initial Food and Drug Administration (FDA) approval for an ICI
(ipilimumab) in 2011 for advanced stage melanoma, efficacy has been demonstrated in a
broad range of both solid tumors and hematologic malignancies. ICIs are now indicated
in the neoadjuvant, adjuvant, advanced/metastatic, and recurrent settings for various
tumor types [1]. Additionally, pembrolizumab became the first anti-neoplastic medication
approved across solid tumors solely based on a biomarker, as a result of early studies
including the phase 2 KEYNOTE-158 trial [2]. As the indications for ICIs expand, so too
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must the medical community’s understanding of their effects, both on tumor biology and
patient-reported outcomes.
While the use of ICIs has improved outcomes in cancer, ICIs are also associated with
multiple adverse effects, such as cancer-related fatigue (CRF), which occurs in up to 25%
of patients. Physical activity has been previously shown to be effective in the milieu
of chemotherapy for decreasing the severity of chemotherapy- and cancer-related side
effects [3–5]. Similarly, physical activity has been shown to reduce CRF and modulate the
immune system through multiple mechanisms in cancer patients [6,7].
Therefore, it has been postulated that physical activity may impact the outcomes of
those being treated with ICIs. Current recommendations are to be as physically active
as an individual’s abilities will allow [8]. Cancer patients are recommended to follow
guidelines for healthy populations, which may not always be appropriate [9], even though
many cancer survivors have reportedly reaped great benefits from individualized fitness
regimens [10].
The utilization of ICIs has increased exponentially, and along with this use there
have been immune-related adverse events. Previous work indicates that physical activity
concurrent with cancer therapy may be useful for alleviating adverse events in cancer
patients; however, this is as yet unknown. The purpose of this scoping review is to describe
how physical activity is conceptualized as concurrent cancer therapy to ICIs, to identify
the evidence available in the field for the addition of physical activity to ICIs, to elucidate
the outcomes of adding physical activity to ICIs, and to identify and analyze knowledge
gaps in the field in order to further future research.
2. Materials and Methods
The scoping review was conducted according to the Joanna Briggs Institute methodology for scoping reviews, which is based predominantly on the protocols established by
Arksey and O’Malley, but also includes the revisions suggested by Levac et al. and Peters
et al. [11–15]. The review followed six steps: (1) defining the research question; (2) identifying relevant studies; (3) study selection; (4) charting the data; (5) collating, summarizing,
and reporting the results; and (6) consultation. Reporting of findings was conducted according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)
guidelines using the PRISMA extension for scoping reviews (PRISMA-ScR) checklist and is
shown in Appendix A [16].
2.1. Inclusion and Exclusion Criteria
The scoping review was intended to include studies of individuals being treated with
ICIs for those cancers for which the FDA has approved the use of ICIs as treatment as of
31 December 2020. The focus of the review was to clarify the concept of physical activity as
concurrent therapy to ICIs, and to describe the outcomes of physical activity as concurrent
therapy to ICIs in our participants of interest. Given the possibility of a scarcity of data,
the decision was made to not limit the study to human studies. For context, the review
included institutional and community care settings. No restrictions were placed on type of
physical activity, so long as the activity was concurrent with administration of ICIs and the
outcomes of both physical activity and concurrent ICI administration were reported. All
full-text, peer-reviewed publications published from January 2010 through to August 2021
were included for consideration. January 2010 was chosen as a start date so as to capture
any published trial data relating to the first ICI approval in 2011.
The search was restricted to articles and reports published in English. It was restricted
to full-text, peer-reviewed articles so as to be certain of the scientific rigor of the results
presented. Abstract-only publications were excluded, as were any papers that failed to
fully elucidate outcomes (editorials, etc.). Though abstracts and editorials can be useful to
help form search strategies, they can lack less-than-favorable results. By their abbreviated
nature, abstracts do not present all data, and so were excluded. Editorials are opinion-only.
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2.2. Search Strategy
The search strategy for this review was the result of prior research in the fields of
prostate cancer and immunotherapy, as well as the strategies recommended by Tawfik
et al. for adapting searches according to database [17]. An experienced search librarian
was also consulted. The full protocol was registered at both Open Science Framework
and Figshare (https://osf.io/kb8pq/?view_only=9df23d7dd1204049a05ff37b893874c8, accessed on 30 August 2021 and https://doi.org/10.6084/m9.figshare.16540152.v3, accessed
on 30 August 2021 respectively).
The following databases were searched: PubMed, CINAHL, Cochrane Library, and
Scopus. The search terms included (but were not limited to): “neoplasms”, “cancer”, “exercise”, “activity”, “physical activit*”, and “immune checkpoint inhibitor”. Further, MeSH
terms and subject headings were also employed. A full search strategy was developed for
PubMed and is shown in Appendix B.
2.3. Data Charting Process and Extraction Items
Three members of the research team (A.L.S., S.S., and N.N.) participated in the data
extraction process. First, titles were screened for duplicates via software (EndnoteX9).
Manual screening was conducted by the same three team members. Second, titles were
screened manually for duplicates. Finally, titles and abstracts were screened based on inclusion/exclusion criteria. Screening was conducted independently, and the inclusion forms
were compared for consistency. Upon agreement, full-text review was then conducted
independently. From each article, the following information was charted: author, year of
publication, title, ICI, country of origin, study type, study population, operationalization of
exercise/physical activity, primary objective(s), and outcome(s)/summary. Blank inclusion
and extraction forms are included in the Supplemental Materials.
2.4. Synthesis of Results
In the event that studies utilized similar physical activity and ICIs, a systematic review
and meta-analysis would be the ideal synthesis tool. However, a narrative synthesis was
instead chosen, given the broad scope of the question, the desire of the research team to
allow for multiple forms of physical activity, and the relatively new nature of the field. The
articles were grouped according to subject type (pre-clinical, clinical). As there was only
1 human study which included prospectively collected data and 3 murine randomized
control trials, a critical appraisal of evidence within trials was deemed unnecessary for
this review.
3. Results
3.1. Selection of Sources of Evidence
The literature search retrieved 800 articles. Computer software eliminated 45 duplicates. An additional 15 duplicates were manually eliminated. The remaining 740 abstracts
were screened and, with the addition of 2 articles found through other sources, 24 articles
were identified for full-text review. After the full-text review, 4 articles remained for inclusion in the scoping review, having fulfilled all inclusion criteria. The most frequently cited
reasons for article exclusion were lack of an ICI and lack of a concurrent physical activity
intervention during ICI therapy (Figure 1).
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Table 1. Cont.
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3.3. Key Findings
The main outcomes measured in the clinical study were feasibility, patient-reported
symptoms, anxiety and depression, toxicity, and patient adherence [21]. Multiple myeloma
patients treated with pembrolizumab were recruited to test the feasibility of a multimodal
support program. The program included care provided by physicians, dieticians, and
exercise physiologists. The patients had low numbers of adverse events both pre- and poststudy, the most prevalent being fatigue and sleep issues. The physical activity intervention
was shown to be feasible with an 85% completion rate. Limitations of this study included
the small sample size, the mixing of cohorts in which patients were both initiating and
pre-established on treatment with ICIs, and the self-selective nature of the control group.
The main focuses of the pre-clinical studies were tumor size and growth rate [18–20].
All three murine studies indicated that physical activity slowed tumor growth, slowed
immune cell proliferation, and improved immune sensitivity [18–20].
Bay et al. tested the addition of physical activity via voluntary wheel running to immune checkpoint blockade (either PD-1 or PD-L1) on tumor growth and gene expression of
immune regulatory molecules [18]. Wheel running alone was found to increase expression
of PD-1, PD-L1 and PD-L2 significantly. In this same model, tumor growth was reduced
by 72% in mice who demonstrated voluntary physical activity when compared to the
inactive control mice (p = 0.13). Mice who participated in voluntary physical activity and
were treated with a PD-L1 inhibitor showed an 83% reduction in the rate of tumor growth
(p < 0.05) compared to the rate of growth in the sedentary group. A 50% rate of tumor
growth reduction was seen in mice with physical activity combined with PD-1 blockade
(p = 0.07) compared to sedentary mice. The researchers found no additional advantage to
administering both PD-1 and PD-L1 blockade along with physical activity.
Gomes-Santos et al. studied the effect of physical activity, concurrent with anti-PD-1
alone or in combination with anti-CTLA-4 treatment, on tumor growth and the tumor
environment [19]. The study used mice to model human breast cancer and treadmills
for physical activity. Physical activity was able to decrease the rate of tumor growth, as
well as induce vessel normalization. Seven days of exercise training in three different
models of breast cancer resulted in reduced tumor burden (approximately 30% decrease
in tumor weight; model 1: ~600 mg vs. 400 mg; model 2: ~600 mg vs. 450 mg; model 3:
~825 mg vs. 600 mg). The tumor microenvironment of treadmill mice had increased
perfusion and decreased hypoxia. There was no change in blood vessel density, but a
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positive impact was reported on the fraction of blood vessels that were perfused. RNA
sequencing also confirmed that there was reprogramming of the tumor microenvironment
towards more oxidative phosphorylation and less immunosuppression. These changes
had important implications on the sensitivity of the breast cancer model; mice treated with
a combination of immunotherapies directed at both PD-1 and CTLA-4 as well as scripted
exercise had delayed tumor growth and decreased tumor volume compared to sedentary
mice. Finally, physical activity prevented CRF in immune-checkpoint-blockade-treated
mice, as measured by preservation of exercise capacity, demonstrated through increased
time to exhaustion (~1500 sec vs. ~2500 sec; p < 0.001) and total running distance ~450 m
vs. ~1000 m; p < 0.001) compared to the control group.
Martín-Ruiz utilized a murine model of non-small cell lung cancer (NSCLC) to study
the effects of physical activity in combination with nivolumab therapy [20]. The animals in
this study experienced both treadmill running to target aerobic capacity, as well as cage
climbing and bar hanging for strength training. Similar to the Bay et al. study, physical
activity alone reduced tumor growth rate in comparison to sedentary mice (p = 0.05). When
nivolumab was added to the regimen, tumor death (p = 0.026) and apoptosis (p = 0.030)
were increased among the physically active mice. As expected, aerobic capacity and
strength improved in the active mice. Of note, neutrophil tumor infiltration was higher in
the physically active group in combination with nivolumab group (p = 0.018) compared to
the inactive group, and VEGF-A expression was higher in the nivolumab group, regardless
of physical activity status.
4. Discussion
The aim of this scoping review was to elucidate the extent of published research
evaluating the effects of concurrent physical activity interventions and the use of ICIs. To
the authors’ knowledge, this is the first scoping review to focus on studies that assess the
concurrent administration of ICIs and a physical activity regimen. Our results identify
a major gap in human-based research in the field. Part of the reason for this may be the
relatively new nature of the medications that are still undergoing trials for approvals in
different cancer types. Another reason may be a lack of trained practitioners to aid patients
as described by Santa Mina et al. [22] This may have led to human studies being proposed
but not reaching completion, and therefore remaining unpublished. Many of the studies
published to date have been during the survivorship phase rather than during active
treatment, which limits the availability of data on the direct synergistic effect of physical
activity on cancer therapy.
As a concept, physical activity is considered to be complementary to immune checkpoint blockade. From pre-clinical to clinical studies, “physical activity” was viewed as
anything from wheel-running, to strength training, to walking, to qi-gong and yoga. The
pre-clinical studies indicate that the combination of physical activity and checkpoint inhibition is advantageous to the patient through decreased tumor growth, improved strength,
decreased fatigue, and improved ability of the immune system to fight cancer.
4.1. Physiology of Exercise and Immunology
There is a growing body of evidence investigating the mechanisms by which exercise
modulates immunity. Much of this research points to effects on natural killer (NK) and
T cells, rather than to components of humoral immune responses [7]. These are also the
immune cells that are targeted by ICIs, indicating that the anti-tumor effects of both exercise
and checkpoint blockade may be synergistic.
It has been shown that sedentary patients have higher proportions of both CD4+ and
CD8+ T cells that express PD-1, a negative immunologic regulator [23]. Meanwhile, CD8+
cytotoxic T cells are mobilized by acute exercise, and thus more able to participate in active
immunity [24]. Exercise further induces the proliferation and activation of T cells against
tumors, likely through adrenergic stimulation [25]. Finally, T cells that undergo repeated
stimulation suffer from both senescence (a decreased ability to replicate partially due to
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telomere shortening) and exhaustion (the loss of vital functions). However, these two
processes of immune impairment are attenuated by the effects of exercise [26].
As the blockade of PD-L1, PD-1, and CTLA-4 by ICIs results in the activation of T
cells, it stands to reason that this effect would be augmented by exercise through the above
mechanisms. In fact, this was demonstrated in a mouse model of breast cancer, which
showed that exercise slowed immunosuppressive elements of the tumor microenvironment
and induced increases in CD8+ T cell activation [27]. This was tested in the presence of
radiotherapy (RT) plus PD-1 blockade. The investigators found that the addition of exercise
to RT+PD-1 blockade increased splenic CD8+ T cells, decreased PD-1 expression on NK
cells, increased markers of NK-cell activation, and ultimately slowed tumor growth.
Although there are clearly physiologic reasons for synergism with immunotherapies, physical activity has also been shown to improve outcomes when combined with
chemotherapy. One study in breast cancer patients found that a physical activity regimen
was adhered to more closely while patients were undergoing therapy, as compared with
when after therapy was complete; and higher adherence occurred during chemotherapy
than during radiotherapy [28]. In lung cancer, across the cancer continuum, increased
physical activity was found to be safe and sought-after by patients, and shown to improve
quality of life [29].
Similarly, a recent study indicated that the combination of diet, physical activity, and
chemotherapy improved the efficacy of chemotherapy in patients with acute lymphoblastic
leukemia [30]. Compared to usual care, those patients who participated with a diet and
physical activity program during treatment saw a reduction in minimal residual disease.
Similarly to the murine results of the Martín-Ruiz et al. study, Reis et al. found
an increase in in both functional and aerobic capacity in human breast cancer patients
undergoing treatment [20,31]. Reis et al. also found a decrease in pain scores and an increase
in strength for those undergoing a physical activity regimen during their chemotherapy.
There was no significant finding for fatigue. Likewise, the OptiTrain group found lower
rates of thrombocytopenia in their exercising group compared to usual care [32].
4.2. Strengths and Limitations
This scoping review had a number of strengths. The review used a strong and
transparent methodology. A protocol was followed and was registered before research
began. A broad search of the literature was conducted in four databases. Finally, the review
was conducted by a multidisciplinary team. The review also had some limitations. To
manage scope, we excluded studies without clearly defined outcomes, as well as abstracts.
However, the abstracts that were eliminated on full scan could have also been eliminated
for lack of concurrent therapy. Another limitation is the use of articles published only in
English in the review. Articles examining the topic in other languages may have been
missed in the search. The study included only four articles, and so the synthesis of results
is limited.
5. Conclusions
The results of the scoping review suggest that the current availability of research is
lacking to inform the use of concurrent administration of physical activity or increased
physical activity and ICIs. Pre-clinical studies suggest that the addition of physical activity,
whether as a prescribed regimen or as a voluntary practice, has benefits both in tumor
growth rate and volume. Those studies also show an improvement in strength and in
immune response. The clinical pilot study showed efficacy for the addition of physical
activity to immunotherapy. Prior studies indicate that the addition of physical activity
benefits chemotherapy. There is a need now to perform more clinical studies combining
physical activity with immunotherapy, so as to inform clinicians and improve outcomes
for patients.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/10
.3390/cancers13246364/s1, supplemental materials 1: Blank inclusion and extraction forms.
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Appendix A. Preferred Reporting Items for Systematic Reviews and Meta-Analyses
Extension for Scoping Reviews (PRISMA-ScR) Checklist
Table A1. PRISMA-ScR Checklist.
Section

Item

PRISMA-ScR Checklist Item

Reported on
Page

Title
Title

1

Identify the report as a scoping review.

1

Abstract

Structured
summary

2

Provide a structured summary that includes (as
applicable): background, objectives, eligibility
criteria, sources of evidence, charting methods,
results, and conclusions that relate to the review
questions and objectives.

1

Introduction

Rationale

Objectives

3

Describe the rationale for the review in the
context of what is already known. Explain why
the review questions/objectives lend
themselves to a scoping review approach.

2

4

Provide an explicit statement of the questions
and objectives being addressed with reference
to their key elements (e.g., population or
participants, concepts, and context) or other
relevant key elements used to conceptualize the
review questions and/or objectives.

2

Methods
Protocol and
registration

Eligibility
criteria

5

Indicate whether a review protocol exists; state
if and where it can be accessed (e.g., a Web
address); and if available, provide registration
information, including the registration number.

2–3

6

Specify characteristics of the sources of
evidence used as eligibility criteria (e.g., years
considered, language, and publication status),
and provide a rationale.

2
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Table A1. Cont.
Item

PRISMA-ScR Checklist Item

Reported on
Page

Information
sources

7

Describe all information sources in the search
(e.g., databases with dates of coverage and
contact with authors to identify additional
sources), as well as the date the most recent
search was executed.

2

Search

8

Present the full electronic search strategy for at
least 1 database, including any limits used, such
that it could be repeated.

Appendix
Table A2

Selection of
sources of
evidence

9

State the process for selecting sources of
evidence (i.e., screening and eligibility)
included in the scoping review.

2

Data charting
process

10

Describe the methods of charting data from the
included sources of evidence (e.g., calibrated
forms or forms that have been tested by the
team before their use, and whether data
charting was performed independently or in
duplicate) and any processes for obtaining and
confirming data from investigators.

3

Data items

11

List and define all variables for which data were
sought and any assumptions and
simplifications made.

3

Critical
appraisal of
individual
sources of
evidence

12

If carried out, provide a rationale for
conducting a critical appraisal of included
sources of evidence; describe the methods used
and how this information was used in any data
synthesis (if appropriate).

3

Synthesis of
results

13

Describe the methods of handling and
summarizing the data that were charted.

3

Section

Results

14

Give numbers of sources of evidence screened,
assessed for eligibility, and included in the
review, with reasons for exclusions at each
stage, ideally using a flow diagram.

4

Characteristics
of sources of
evidence

15

For each source of evidence, present
characteristics for which data were charted and
provide the citations.

4–6

Critical
appraisal within
sources of
evidence

16

If carried out, present data on critical appraisal
of included sources of evidence (see item 12).

3

Results of
individual
sources of
evidence

17

For each included source of evidence, present
the relevant data that were charted that relate to
the review questions and objectives.

4–6

Synthesis of
results

18

Summarize and/or present the charting results
as they relate to the review questions
and objectives.

4, 6

Selection of
sources of
evidence
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Section

Item

PRISMA-ScR Checklist Item

Reported on
Page

Discussion

Summary of
evidence

19

Summarize the main results (including an
overview of concepts, themes, and types of
evidence available), link to the review questions
and objectives, and consider the relevance to
key groups.

Limitations

20

Discuss the limitations of the scoping
review process.

8

21

Provide a general interpretation of the results
with respect to the review questions and
objectives, as well as potential implications
and/or next steps.

8

22

Describe sources of funding for the included
sources of evidence, as well as sources of
funding for the scoping review. Describe the
role of the funders of the scoping review.

9

Conclusions

Funding

7

Appendix B
Table A2. PubMed Search.
Database

Search Terms

Results

PubMed

(“bladder cancer”[All Fields] OR “bc”[All Fields] OR “cancer*”[All Fields] OR
“cc”[All Fields] OR “cervical cancer”[All Fields] OR “cHL”[All Fields] OR
“classical Hodgkin’s lymphoma”[All Fields] OR “Colorectal Neoplasms”[MeSH
Terms] OR “metastatic colorectal cancer”[All Fields] OR “colorectal cancer”[All
Fields] OR “CRC”[All Fields] OR “CSCC”[All Fields] OR “cutaneous squamous
cell carcinoma”[All Fields] OR “endometrial cancer”[All Fields] OR “ec”[All
Fields] OR “Endometrial Neoplasms”[MeSH Terms] OR “esophageal squamous
cell carcinoma”[All Fields] OR “ESCC”[All Fields] OR “gastric carcinoma”[All
Fields] OR “gc”[All Fields] OR “gastroesophageal junction carcinoma”[All
Fields] OR “GEJ carcinoma”[All Fields] OR “head and neck cancer”[All Fields]
OR “HNC”[All Fields] OR “HNSC”[All Fields] OR “Head and Neck
Neoplasms”[MeSH Terms] OR “hepatocellular carcinoma”[All Fields] OR
“HCC”[All Fields] OR “locally advanced”[All Fields] OR “lymphoma*”[All
Fields] OR “Lymphoma”[MeSH Terms] OR “Melanoma”[MeSH Terms] OR
“MCC”[All Fields] OR “Merkel cell carcinoma”[All Fields] OR “metastatic
Merkel Cell carcinoma”[All Fields] OR “metastatic melanoma”[All Fields] OR
“metastatic squamous NSCLC”[All Fields] OR “metastatic NSCLC”[All Fields]
OR “metastatic non-squamous NSCLC”[All Fields] OR “non-squamous
NSCLC”[All Fields] OR “carcinoma, non-small cell lung”[MeSH Terms] OR
“carcinoma”[All Fields] OR “non-small cell”[All Fields] OR “lung”[All Fields]
OR “non-small-cell lung carcinoma”[All Fields] OR “nsclc”[All Fields] OR
“non-small cell lung cancer”[All Fields] OR “unresectable stage III NSCLC”[All
Fields] OR “Neoplasms”[MeSH Terms] OR “neoplasia*”[All Fields] OR
“pm”[All Fields] OR “pleural mesothelioma”[All Fields] OR “PMBCL”[All
Fields] OR “primary mediastinal large B cell lymphoma”[All Fields] OR
“advanced RCC”[All Fields] OR “RCC”[All Fields] OR “renal cell
carcinoma”[All Fields] OR “small cell lung cancer”[All Fields] OR “SCLC”[All
Fields] OR “solid tumor”[All Fields] OR “squamous cell head and neck
cancer”[All Fields] OR “triple-negative breast cancer”[All Fields] OR
“TNBC”[All Fields] OR “unresectability”[All Fields] OR “unresectable”[All
Fields] OR “unresected”[All Fields] OR “urinary bladder neoplasms”[All
Fields] OR “urothelial carcinoma”[All Fields] OR “metastatic urothelial
carcinoma”[All Fields])

360
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Table A2. Cont.
Database

Search Terms

Results

AND
(“exercise*”[All Fields] OR “Exercise”[MeSH Terms] OR “Exercise Therapy”[All
Fields] OR “Exercise Therapy”[MeSH Terms] OR (“physical
examination”[MeSH Terms] OR “physical examination”[All Fields] OR
“physical”[All Fields] OR “physically”[All Fields] OR “physicals”[All Fields]
OR “physical activit*”[All Fields] OR “weight-bearing exercise”[All Fields] OR
“weight-bearing”[All Fields] OR “weight-bearing training”[All Fields] OR
“strength training”[All Fields] OR “training”[All Fields] OR “aerobic”[All
Fields] OR “aerobically”[All Fields] OR “Exercise”[All Fields] OR “aerobics”[All
Fields] OR “aerobic training”[All Fields] OR “aerobic exercise”[All Fields] OR
“aerobic activit*”[All Fields] OR “rehabilitant”[All Fields] OR “rehabilitants”[All
Fields] OR “rehabilitate”[All Fields] OR “rehabilitated”[All Fields] OR
“rehabilitates”[All Fields] OR “rehabilitating”[All Fields] OR
“Rehabilitation”[MeSH Terms] OR “Rehabilitation”[All Fields] OR
“rehabilitations”[All Fields] OR “rehabilitative”[All Fields] OR
“Rehabilitation”[MeSH Subheading] OR “rehabilitations”[All Fields] OR
“rehabilitational”[All Fields] OR “rehabilitator”[All Fields] OR
“rehabilitators”[All Fields] OR “physical rehabilitation”[All Fields] OR
“HIIT”[All Fields] OR “high intensity interval training”[All Fields] OR
“therapeutic exercise”[All Fields] OR “aerobic conditioning”[All Fields] OR
“rehabilitative exercise”[All Fields] OR “physical therapy modalities”[MeSH
Terms] OR (“physical”[All Fields] AND “therapy”[All Fields] AND
“modalities”[All Fields]) OR “physical therapy modalities”[All Fields] OR
“physiotherapies”[All Fields] OR “physiotherapy”[All Fields] OR “resistance
training”[All Fields] OR “Exercise Movement Techniques”[MeSH Terms]))
AND
(“immunomodulatory”[All Fields] OR “immune therapy”[All Fields] OR
“immune checkpoint inhibitors”[All Fields] OR “ICI”[All Fields] OR “anti-PD-1
monoclonal antibody”[All Fields] OR “pembrolizumab”[Supplementary
Concept] OR “pembrolizumab”[All Fields] OR
“pembrolizumab”[Supplementary Concept] OR “pembrolizumab”[All Fields]
OR “keytruda”[All Fields] OR “anti-CTLA-4 monoclonal antibody”[All Fields]
OR “tremelimumab”[Supplementary Concept] OR “tremelimumab”[All Fields]
OR “nivolimumab”[All Fields] OR “nivolumab”[MeSH Terms] OR
“nivolumab”[All Fields] OR “opdivo”[All Fields] OR “ipilimumab”[MeSH
Terms] OR “ipilimumab”[All Fields] OR “ipilimumab”[MeSH Terms] OR
“ipilimumab”[All Fields] OR “yervoy”[All Fields] OR
“avelumab”[Supplementary Concept] OR “avelumab”[All Fields] OR
“avelumab”[Supplementary Concept] OR “avelumab”[All Fields] OR
“bavencio”[All Fields] OR “durvalumab”[Supplementary Concept] OR
“durvalumab”[All Fields] OR “cemiplimab”[Supplementary Concept] OR
“cemiplimab”[All Fields] OR “durvalumab”[Supplementary Concept] OR
“durvalumab”[All Fields] OR “imfinzi”[All Fields] OR
“cemiplimab”[Supplementary Concept] OR “cemiplimab”[All Fields] OR
“libtayo”[All Fields] OR “atezolizumab”[Supplementary Concept] OR
“atezolizumab”[All Fields] OR “tecentriq”[All Fields] OR “PD1”[All Fields] OR
“PDL1”[All Fields] OR “CTLA4”[All Fields] OR “PD-1”[All Fields] OR
“PD-L1”[All Fields] OR “ctla 4 antigen”[MeSH Terms] OR “ctla 4 antigen”[All
Fields] OR “ctla 4”[All Fields])
AND
(2010/01/01:2021/08/31[Date-Publication] AND “english”[Language]))) AND
((fft[Filter]) AND (2010/1/1:2021/8/31[pdat]) AND (english[Filter]) AND
(alladult[Filter]))
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